Academic Journal
Three-year outcomes of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A real-world study.
| Τίτλος: | Three-year outcomes of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A real-world study. |
|---|---|
| Μεταγλωττισμένος Τίτλος: | Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real. |
| Συγγραφείς: | Zamarrón de Lucas E; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. Electronic address: Ester.zamarron@gmail.com., Crespo Catalán C; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Romero Campos B; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Sanz Sanjosé B; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Longás Ouzzine M; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Aponte Guevara CS; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Álvarez-Sala Walther R; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España., Prados Sánchez MC; Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. |
| Πηγή: | Medicina clinica [Med Clin (Barc)] 2026 Aug; Vol. 166 (8), pp. 107448. Date of Electronic Publication: 2026 May 27. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English; Spanish; Castilian |
| Στοιχεία περιοδικού: | Publisher: Elsevier España Country of Publication: Spain NLM ID: 0376377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1578-8989 (Electronic) Linking ISSN: 00257753 NLM ISO Abbreviation: Med Clin (Barc) Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2009- > : Madrid : Elsevier España Original Publication: Barcelona : Ediciones Doyma, S.A. |
| Ιατρικοί όροι (MeSH): | Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/microbiology , Cystic Fibrosis*/physiopathology , Benzodioxoles*/therapeutic use , Quinolones*/therapeutic use , Indoles*/therapeutic use , Aminophenols*/therapeutic use , Pyrrolidines*/therapeutic use , Chloride Channel Agonists*/therapeutic use , Pyridines*/therapeutic use, Sputum/microbiology ; Humans ; Female ; Adult ; Longitudinal Studies ; Male ; Treatment Outcome ; Drug Combinations ; Young Adult ; Forced Expiratory Volume ; Time Factors ; Pyrazoles ; Quinolines |
| Περίληψη: | Introduction: CFTR modulators have significantly changed the prognosis of cystic fibrosis (CF), although data on their long-term clinical and microbiological impact in adults in real-world practice remain limited. Objective: To analyze the clinical, functional, and microbiological outcomes at 36 months in adults with CF treated with elexacaftor/tezacaftor/ivacaftor (ETI). Methods: A longitudinal observational study was conducted in adults with CF. Lung function, number of exacerbations, weight, and sputum cultures were assessed at baseline and at 12, 24, and 36 months after initiation of ETI. Results: A total of 55 patients were included (43.6% female; mean age 32±13 years). FEV1 improved at 12 months and remained stable at 36 months. Exacerbations decreased, and weight increased progressively. The proportion of patients with potentially pathogenic microorganisms decreased from 93.1% at baseline to 36.2% at 36 months. Patients without microbiological isolation showed better lung function and fewer exacerbations. Conclusions: In real-world clinical practice, ETI is associated with improvements in lung function, weight, and exacerbations, as well as a reduction in the isolation of potentially pathogenic microorganisms in sputum at 36 months. (Copyright © 2026 Elsevier España, S.L.U. All rights reserved.) |
| Contributed Indexing: | Keywords: Cystic fibrosis; Evolución; Evolution; Fibrosis quística; Microbiology; Microbiología; Moduladores; Modulators |
| Substance Nomenclature: | 0 (Benzodioxoles) 0 (Quinolones) 0 (Indoles) 0 (Aminophenols) 0 (Drug Combinations) 0 (elexacaftor, ivacaftor, tezacaftor drug combination) 0 (Pyrrolidines) 0 (Chloride Channel Agonists) 0 (Pyridines) 0 (Pyrazoles) 0 (Quinolines) |
| Entry Date(s): | Date Created: 20260527 Date Completed: 20260723 Latest Revision: 20260723 |
| Update Code: | 20260724 |
| DOI: | 10.1016/j.medcli.2026.107448 |
| PMID: | 42202689 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1578-8989 |
|---|---|
| DOI: | 10.1016/j.medcli.2026.107448 |